Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NovelStem InternationalNSTM Return-on-Tangible-Equity is 0.00% as of Mar. 2026. The stock has 2 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, NovelStem International ranks better than 99.48% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. NovelStem International's annualized net income for the quarter that ended in Mar. 2026 was $-0.22 Mil. NovelStem International's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $-2.04 Mil. Therefore, NovelStem International's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.
The historical rank and industry rank for NovelStem International's Return-on-Tangible-Equity or its related term are showing as below:
NSTM'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -94.27 Med: -35.23 Max: 88.56
Current: Negative Tangible Equity
During the past 13 years, NovelStem International's highest Return-on-Tangible-Equity was 88.56%. The lowest was -94.27%. And the median was -35.23%.
NSTM's Return-on-Tangible-Equity is ranked better than 99.48% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.14
vs NSTM: Negative Tangible Equity
NovelStem International (OTCPK:NSTM) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
NovelStem International Return-on-Tangible-Equity Related Terms
NovelStem International Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for NovelStem International's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovelStem International Return-on-Tangible-Equity Chart
NSTM vs NOTVQ, PRPH, IDTA: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, NovelStem International's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovelStem International Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NovelStem International's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where NovelStem International's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
NovelStem International (NSTM) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NovelStem International and its competitors. According to the industry distribution chart, NovelStem International ranks #1 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 0.5%.
Is NovelStem International's Return-on-Tangible-Equity too high?
NovelStem International's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, NovelStem International ranks #1 out of 191 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does NovelStem International's Return-on-Tangible-Equity compare to NOTVQ and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, NovelStem International ranks #1 out of 191 companies for Return-on-Tangible-Equity. This places NovelStem International in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NovelStem International and its competitors. NovelStem International's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovelStem International stock overvalued right now?
NovelStem International (NSTM) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For NovelStem International (NSTM), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NovelStem International Corp is a holding company. Through its subsidiaries, the company is engaged in the development and commercialization of diagnostic technology that can predict patients' anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. The company also has an interest in a book publishing franchise.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSTM has been successfully added to your 
